To test for significance of seasonality, we tested whether the model was statistically significant. Mortality was analyzed by survival analysis using Cox’s proportional hazard rate including censoring. The follow-up time for one person was from the day the fracture occurred to death or the censoring date in January 1, 2009. The analyses were

performed using the Statistical Package for Rapamycin in vitro Social Sciences version 15.0 (SPSS, Chicago, IL, USA), Microsoft Office Excel version 2007 and the statistical program R, version 2.11.0 (The R Foundation for Statistical Computing). Results Fracture incidence and time trends Of the 603 fractures, 73% (95% CI: 69.5, 76.5) occurred in women providing a female:male ratio of 2.7. The mean age at fracture in this population (aged 50 years and above) was 80.0 years (95% CI: 79.1, 80.9) in women and 76.7 years (95% CI: 75.1, 78.3) https://www.selleckchem.com/products/ulixertinib-bvd-523-vrt752271.html in men (p < 0.001). The median age at hip fracture was 81.7 and 79.3 years in women and men, respectively. Age at fracture did not change during the 15 years, neither in women (p = 0.43) nor in men (p = 0.26). The incidence of hip fractures rose exponentially with increasing

age from 5.8 to 349.2 per 10,000 in men, CDK inhibitor and from 8.7 to 582.2 per 10,000 in women (Table 1 and Fig. 1). Table 1 Age- and sex-specific annual incidence of hip fractures Anidulafungin (LY303366) in Harstad, Northern Norway Age groups (years) Number of hip fractures Person years in total Incidence per 10,000 (SD) 95% CI Men  50–54 7 12,060 5.8 (2.2) 1.5, 10.1  55–59 6 10,095 5.9 (2.4) 1.2, 10.7  60–64 6 7,740 7.8 (3.2) 1.5, 14.0  65–69 20 6,360 31.4 (7.0) 17.7, 45.2  70–74 20 5,595 35.7 (8.0) 20.1, 51.4  75–79 27 4,545 59.4 (11.4) 37.0, 81.8  80–84 37 2,970 124.6 (20.5) 84.4, 164.7  85–89 28 1,050 266.7 (50.4) 167.9, 365.4  90+ 11 315 349.2 (105.3) 142.8, 555.6 Women  50–54 10 11,520 8.7 (2.7) 3.3,14.1  55–59 13 9,810 13.3 (3.7) 6.0, 20.5

 60–64 11 7,980 13.8 (4.2) 5.6, 21.9  65–69 22 6,990 31.5 (6.7) 18.3, 44.6  70–74 41 6,750 60.7 (9.5) 42.2, 79.3  75–79 74 6,075 121.8 (14.2) 94.1, 149.6  80–84 127 4,620 274.9 (24.4) 227.1, 322.7  85–89 81 2,460 329.3 (36.6) 257.6, 401.0  90+ 62 1,065 582.2 (73.9) 437.2, 727.1 Fig. 1 Hip fracture incidence rates pr 10,000 in women and men in Harstad (1994–2008) and Oslo (1996–1997), Norway Table 2 displays the incidence rates in Harstad compared with reported rates from four studies from other parts of Norway.